Ergoteles’s Arcus Biosciences RCUS Stock Holding History

Ergoteles’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35,305	Closed	-$730K	–	1679
2022 Q4	$730K	Buy	+35,305	New	+$972K	0.03%	571
2022 Q2	–	Sell	-39,966	Closed	-$1.26M	–	1936
2022 Q1	$1.26M	Buy	+39,966	New	+$1.34M	0.05%	365
2021 Q4	–	Sell	-6,600	Closed	-$230K	–	1530
2021 Q3	$230K	Buy	+6,600	New	+$205K	0.01%	919

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ergoteles's RCUS Position: Q1 2023 in Review

Ergoteles sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 35,305 shares — an estimated $730K sold.

Ergoteles first reported a position in RCUS in Q3 2021 and held it in 3 quarters. The position peaked at $1.26M in Q1 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

Ergoteles reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 35,305 Arcus Biosciences shares in Q1 2023, an estimated $730K.
Ergoteles first reported a position in Arcus Biosciences in Q3 2021 and held it in 3 quarters.
Ergoteles's Arcus Biosciences position peaked at $1.26M in Q1 2022.
179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.